OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback